PVA Foam Iodine Release for Wound Antimicrobial Action
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing iodine-based antimicrobial solutions face limitations due to high toxicity, rapid release, and short duration of action, particularly in water-soluble iodophor complexes which are not suitable for use on open wounds or in high-protein environments, leading to cytotoxicity and premature dissipation of iodine, necessitating frequent application and causing patient discomfort.
Innovation Solution
A PVA foam with increased density and controlled iodine release is achieved through a pore former foaming process using starch as a pore former, which is biocompatible and allows for extended iodine release duration and reduced toxicity, combined with a lipid-based semi-solid to minimize pain and maintain a consistent release profile.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If water-soluble iodophor complexes are used for antimicrobial action, then iodine is released to kill microorganisms, but the release is too rapid causing cytotoxicity and premature dissipation
Solution Approach 1:
The patent employs a hydrophobic porous foam matrix to encapsulate iodine, controlling its release through the porous structure. The hydrophobic nature of the foam prevents rapid dissolution in aqueous environments, while the porous architecture allows gradual iodine diffusion, achieving sustained release over days rather than minutes or hours.
Solution Approach 2:
The patent changes the physical and chemical parameters of the iodine delivery system by using a hydrophobic foam matrix with specific density and pore structure. This transforms the release mechanism from rapid dissolution (water-soluble) to controlled diffusion (hydrophobic), extending the release duration and reducing peak concentration to avoid cytotoxicity.
2Reliability
If high concentration of iodine is used to ensure antimicrobial efficacy, then microbial killing is effective, but toxicity to living cells increases
Solution Approach 1:
The patent implements periodic or sustained low-level iodine release rather than a single high-concentration dose. The foam matrix maintains a steady state concentration of free iodine at the application site over an extended period, providing continuous antimicrobial action at sub-toxic levels.
Solution Approach 2:
The patent transforms the concentration-time profile of iodine delivery from a sharp peak (high concentration, short duration) to a sustained plateau (low concentration, long duration). This parameter change in release kinetics maintains microbial cidal potency while reducing cytotoxicity.
3Reliability
If elemental iodine is used in tincture form for antimicrobial action, then broad-spectrum activity is achieved, but volatility causes loss of potency over time
Solution Approach 1:
The patent uses a porous foam matrix to physically contain elemental iodine, preventing its volatilization. The porous structure provides a large surface area for iodine incorporation while the hydrophobic matrix reduces vapor pressure, minimizing loss of iodine to the atmosphere over time.
4Reliability
If frequent application of iodine is performed to maintain antimicrobial effect, then continuous protection is achieved, but patient discomfort and treatment complexity increase
Solution Approach 1:
The patent achieves continuous useful action through the sustained release mechanism of the hydrophobic foam. A single application provides continuous low-level iodine release over several days, eliminating the need for frequent reapplication and reducing treatment complexity while maintaining continuous antimicrobial protection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting PVA foam exhibits controlled iodine release profiles, reducing toxicity and frequency of dressing changes, providing longer-lasting antimicrobial action and improved patient comfort with enhanced flexibility and strength, suitable for use in anatomical spaces and wound healing.
Implementation Method 1
pore former foaming process using starch as a pore former
Implementation Method 2
PVA foam with increased density and controlled iodine release is achieved through a pore former foaming process
Implementation Method 3
controlled iodine release profiles
Implementation Method 4
controlled release of iodine
Implementation Method 5
combined with a lipid-based semi-solid to minimize pain and maintain a consistent release profile
Data Source
AI summary
A biocompatible controlled release form of complexed iodine is achieved by a complexation of polyvinyl alcohol based foam and characterized by a residual starch component to optimize iodine release profiles. The resulting iodine complexed polyvinyl alcohol foam may be utilized locally as an antimicrobial agent that releases controlled amounts of iodine sufficient to kill microbes for extended durations without excessive bulk and rigidity.